Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100-and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.
Introduction
Patients with peripheral arterial disease (PAD) are increasing drastically together with the aging of population, as well as with the expansion of the number of patients with diabetes mellitus, dyslipidemia and hypertension, which elevates the risk atherosclerosis [1] . Acute occlusion of arteries such as plaque rupture and thrombosis can cause a worsening of symptoms in chronic PAD [2] . Among PAD pathophysiology, above acute artery occlusion often requires urgent treatment, because the tissue necrosis proceeds faster than growth of the collateral vessels, which can supply sufficient blood flow to restore the peripheral tissues. These situations are called acute limb ischemia (ALI) and could be life threatening with high risk for limb loss. Bypass-surgery and/or endovascular procedure, such as stent/stent graft insertion and balloon angioplasty, are the last resource against these conditions [3] , though these procedures include great invasion or often require repeated applications, which are a great burden to PAD patients. Moreover, the pharmacological alternatives used in the clinic, such as prostaglandin E1, are limited due to their low biostability and efficiency [4] . Therefore, the development of effective pharmacological approaches for noninvasively treating ALI is an imperative need. Nanomedicines, i.e. nano-scaled drug carriers, hold great potential for developing targeted therapies, and could be a promising approach for selectively addressing PAD. Among clinically translationable nanomedicines, self-assembled structures of poly(ethylene glycol) (PEG)-based block copolymers, such as micelles and vesicles, present unique advantages for developing targeted therapies, including their high biocompatibility, controlled size, and the ability to load a wide range of https://doi.org/10.1016/j.jconrel.2018.07.049 Received 30 November 2017; Received in revised form 24 June 2018; Accepted 31 July 2018 therapeutic agents [5] [6] [7] [8] . Moreover, these self-assembled systems can achieve selective penetration and retention in hyperpermeable tissues, such as tumors and inflamed sites, based on the leakiness of their vasculatures [6, 9] . Indeed, we have recently shown the ability of rapamycin-loaded polymeric micelles to accumulate in abdominal aortic aneurysms in an animal model, leading to the suppression of the aneurysm growth [10] . However, the size of nanomedicines, which has been shown to critically affect the targeting process in tumors, may also determine the accumulation of nanomedicines in vascular disorders. Therefore, understanding how the sizes of nanomedicines affect the PAD targeting ability could provide essential information for developing effective treatment strategies.
Herein, we studied the targeting ability of size-modulated nanomedicine analogues against a novel inflammatory model of PAD. To evaluate the accumulation and retention of the nanomedicine analogues in ischemic lesions of PAD, we developed an ALI model in rats presenting the formation of collateral arteries accompanied with inflammation [11] , as the driving force for collateral artery development, such as the increase of fluid shear stress [12] , is stronger in the acute ischemic phase rather than in chronically proceeding stenosis [13] . As nanomedicine analogues, we used fluorescent-labeled cross-linked polyion complex (PIC) micelles (PIC micelles) and vesicles (PICsomes), which are prepared by self-assembly of poly(ethylene glycol) (PEG)-based block aniomers and block/homo catiomers by electrostatic interaction. These nanomedicine analogues offer the abovementioned features of self-assembled structures, and have demonstrated enhanced therapeutic responses against various disease models [6, 10, 14]. Moreover, their particle size can be precisely controlled by adjusting the concentration of the component polymers and their composition [8] .
Our observations indicated the relevance of controlling the size of nanomedicine analogues for targeting PAD, with 100 nm systems achieving high accumulation in the lesions, and suggest the potential of engineered nanomedicines for developing therapies against vascular diseases.
Material and methods

Animal experiments
All procedures were performed as recommended by the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th edition, 2011). All protocols were approved by the Institutional Animal Care and Use Committee of the University of Tokyo (Permit Number: M-P13-126 and M-P15-034) and were performed in accordance with the institutional guidelines as stated by the University of Tokyo.
Male Sprague-Dawley rats (SD rats), fed a normal diet, were used in the experiments. The animals were kept in an air-conditioned (21°C ± 1°C) with a 12 h light-dark cycle. In an isolation rack there were 2 companions at most, and they had free access food and water.
Establishment of ALI model and anatomical pattern of collateral development
SD Rats (10-11 weeks, 400-500 g; CLEA Japan, Inc., Tokyo, Japan) were anesthetized with inhalation of 2-2.5% isoflurane, with concentration adjustments if slight movement of the rats was detected. Therefore, the heart rate and respiratory rate were stable during the entire procedure. A 20 mm oblique incision was made on left inguinal of the rat, and then left femoral artery was resected from just proximal to caudal epigastric artery, to just distal to superficial caudal epigastric artery (Fig. 1) .
Fourteen days later, blood flow of bilateral hindlimbs were evaluated by Laser Doppler imager (moorLDI2-IR®, Moor Instrument Ltd., Devon, UK) under general anesthesia as described above. After that, midline abdominal incision was made and retroperitoneal membrane was bluntly resected and abdominal aorta was exposed. A 20-gauge polyethylene infusion catheter (Terumo, Tokyo, Japan) was induced into abdominal aorta antegradely. Rats were euthanized by injection of overdose of pentobarbital from the inferior vena cava (IVC). After confirmation of cardiorespiratory arrest, the IVC was cut down, and then, a mixed solution of lead oxide (20 g; Wako, Tokyo, Japan), gelatin (0.3 g; Wako), and distilled water (10 mL) was injected by using the catheter [15] . In addition to the radiocontrast ability, lead oxide has vivid orange color. Thus, the arteries containing those mixed solution are also well recognizable to the naked eyes. By reference to fluoroscopic images, we dissected the collateral vessels guided by the orange color and analyzed the anatomic pattern of collateral development in this model. This experiment was repeated five times for ALI models and three times for sham operation.
Evaluation of inflammatory reaction of early phase of the ALI model
ALI models were prepared in same manner as described in Section 2.2. Fourty-eight hours after femoral artery resection, SD rats were euthanized and bilateral caudofemoralis (CF), semimembranous (SM), and semitendonous (ST) muscles were resected. Cryopreserved blocks of those muscles were prepared for immunohistochemical staining. Tissue blocks were sliced with 10 μm thickness and fixed for 10 min with ice-cold acetone. Epitope retrieval was carried out with Target Retrieval Solution (1×; S1699, Dako Inc., CA, USA) for 20 min at 70°C. The tissues were further incubated with Carbo-free Blocking Solution (1×; SP-5040, Vector Laboratories, Inc., CA, USA) and PeroxidaseBlocking Solution (S2023, Dako Inc., CA, USA) for 30 min at room temperature (r.t.). Samples were then incubated with anti-CD68 antibody (1:100; Anti Rat Macrophages (CD68) Mouse monoclonal IgG1, clone ED1, T-3003, BMA Biomedicals, Augst, Switzerland) for 1 h at room temperature. Secondary antibody conjugation was performed with LSAB®2 System-HRP kit (K0609, Dako Inc., CA, USA). Finally, DAB staining was done with DAB Peroxidase Substrate kit (SK4100, Vector Lab. Inc., CA, USA) and nuclei were stained with Mayer's hematoxylin solution. Slides were photographed at 400× magnification. DAB-stained area was measured by ImageJ software.
Synthesis of nanomedicines
We prepared Cy5-labeled PIC micelles having diameters of 30 nm (PICs-30), and PICsomes with 100 and 200 nm (PICs-100, −200), by mixing homo-or block-catiomer and block aniomer as described in our previous work [8] . Briefly, the block aniomer, poly(ethylene glycol)-b- [Bu-P(Asp-AP); 1.0 mg/mL] were mixed and vigorously stirred in 10 mM phosphate buffer (pH 7.4) to form PICsomes and PIC micelles. Then, EDC solution (10 mg/mL, 10 eq. vs. the -COOH group in the block aniomers) was added to the solution, and the reaction was continued overnight. The obtained cross-linked PICsomes and PIC micelles were purified by filtration (Vivaspin 6, molecular weight cutoff [MWCO]: 300,000; Sartorius Stedim Biotech GmbH, Goettingen, Germany). Diameter and polydispersity index (PDI) were determined using dynamic light scattering (DLS; Zetasizer® Nano-ZS instrument, Malvern Instruments, Malvern, UK). The concentration of nanomedicines can be assessed by measuring the Cy-5 fluorescent intensity in the solution.
Evaluation of accumulation of nanomedicine analogues
At least 7 days before the in vivo imaging system (IVIS) measurements, alfalfa-free diet (iVid® #2/3; Oriental Yeast Co., Tokyo, Japan) was supplied to the male SD rats (8 weeks, 250-350 g; Charles River Laboratories Japan, Inc., Yokohama, Japan) for minimizing the autofluoresence. Other conditions, such as preparation of the left hindlimb acute ischemia model and their breeding, were the same as described in Section 2.2.
After 24 h from arterial resection, nanomedicines solution (1 μL/1 g body weight) was injected systemically from lateral tail vein, and then rats were sacrificed with overdose pentobarbital injection. Tissues such as bilateral CF, SM, and ST muscles were resected and evaluated by IVIS (Xenogen, CA, USA). 
Immunofluorescence histology
To evaluate the location of Cy5-labeled nanomedicine analogues, immunohistochemistry (IHC) was performed. Slide preparation was carried out as described in Section 2.3. until blocking of non-specific conjugation. Samples were then incubated with primary antibody, i.e., anti-CD68 antibody (1:50; Anti Rat Macrophages (CD68) Mouse monoclonal IgG1, clone ED1, T-3003, BMA Biomedicals, Augst, Switzerland) or anti-α-SMA antibody (1:100; Monoclonal Mouse AntiHuman Smooth Muscle Actin, Clone 1A4, M0851, Dako Inc., CA, USA) for 1 h at room temperature. After PBS washing, samples were reacted in dark with Alexa Fluor® 555-labeled secondary antibody (1:200; ab150118, Goat Anti-Mouse IgG H&L (Alexa Fluor® 555) preadsorbed, Abcam, Cambridge, UK) for 1 h at r.t. Nuclear was also stained by 15 min incubation with Hoechst 33,342 (1:1000; Thermo Scientific, Waltham, MA, USA). Obtained sections were analyzed by confocal laser scanning microscopy (LSM® 780, Carl Zeiss, Oberkochen, Germany).
Statistical analysis
The distribution characteristics are presented with mean ± standard error. Significance tests were performed by t-tests, or paired ttests if possible, for two groups and Turkey-Kramer's method for multiple comparison tests. All statistical analyses were performed with JMP® Pro 13.0 (SAS Institute Inc.).
Results
Evaluation of limb ischemia and collateral growth
Laser Doppler blood flow imager showed that blood flow of the left hindlimbs of ALI models decreased to 61.9 ± 6.2% compared to the right hindlimbs, without any tissue necrosis. (Fig. 2A) .
The collateral arteries were detected in the CF, SM, and ST ( Fig. 2B-E) . The largest collateral artery was detected in the CF of 1 model and in the SM of 4 models. Thus, we concluded that major collateral arteries were developed in CF and SM.
All the collaterals arose from the internal iliac artery and ran into the popliteal artery. Sham operations showed micro arteriolar anastomose in the same sites as these collateral arteries. (Fig. 2F-G) .
Evaluation of inflammatory reaction of early phase of the ALI model
Photomicrographs of both healthy and ischemic muscles, i.e., CF (A and B), SM (C and D) and ST (E and F) were shown in Fig. 3 , and the total area of CD68-stained lesion was listed in Table 1 . CD68-positive cells localized around vessels between muscular fibers (Fig. 3B, D and  F) . The SM muscle of the ischemic side showed significantly larger CD68-positive area than that of the healthy side (p = .009). The CF muscles of the ischemic side tended to have larger CD68-positive area (p = .053). There was no significant difference between the ST muscles of the ischemic side and the healthy side (p = .82).
Synthesis of nanomedicines
The size distribution of the PIC micelles and PICsomes was determined by dynamic light scattering (Zetasizer® Nano-ZS instrument, Malvern Instruments, Malvern, UK). As shown in Fig. 4 and Table 2 , PIC nanomedicine had mean diameter of 31 ± 0.98 nm, 99 ± 1.12 nm and 205 ± 5.65 nm respectively. The RFU of prepared PIC micelles and PICsomes were adjusted into equal value (30,000 measured by NanoDrop® 3300, Thermo Scientific, Wilmington, DE, USA) by addition of PBS.
Evaluation of nanomedicines accumulation
IVIS measurements were performed after administrations of PICs-30, −100 or −200. Rats injected with PICs-100 and -200 represented the accumulation of fluorescent particles into the ischemic side in CF and SM, whereas PICs-30 injected muscles did not show any fluorescent signals (Fig. 5) . The maximum radiant efficiency of the CF SM, and ST muscles were summarized in Fig. 6 . In the ischemic side of 24 h after injection of PICs-100 group (Fig. 6B) (Fig. 6B ).
In the PICs-100 group, the maximum radiant efficiency of CF and SM of the ischemic side were significantly higher than that of the healthy side, in PICs-100 group of both at 24 (Fig. 6B ) and 72 h (Fig. 6E ) after injection (CF: p = .0002 and 0.006, SM: p = .001 and 0.003, respectively), but ST did not show significant difference in both time points (p = .24 and 0.47, respectively). At 24 h after injection, PICs-200 group also showed significant differences in CF and SM (Fig. 6C p = . 002 and .002, respectively). The ratios of the maximum radiant efficiency of the ischemic side to that of healthy side were calculated for all three muscles. As shown in Fig. 7A , at 24 h after injection, the significant differences of accumulations were found between PICs-30 and PICs-100 in CF and SM (p = .01 and 0.001), and between PICs-100 and PICs-200 in CF (p = .04). At 72 h after injection (Fig. 7B) , statistically significant differences were also appeared between PICs-30 and PICs-100 in SM (p = .001) and between PICs-100 and PICs-200 in SM (p = .02). No difference was found between PICs-30 and PICs-200 during this experiment. Moreover, we evaluated more detailed time profiles of PICs-100 and -200 accumulation against SM muscles. Subtracted total radiant efficiencies (STRE) of healthy side from the ischemic side were presented in Fig. 8 . The mean area under curves of PICs-100 and -200 were 431.5 ± 5.6 × 10 7 and 228.0 ± 3.3 × 10 7 [photons·h/s/cm 2 / sr], respectively.
Immunofluorescent histology
Laser confocal microscopy showed Cy-5 signal of PICs-100 as red pixels ( Fig. 9 and Supplementary Figs. 1-2) . They distributed around α-SMA positive arterioles (Fig. 9A, Supplementary Fig. 1 ). Fig. 9B and Supplementary Fig. 2 showed the PICs-100 signals and CD-68 positive cells (macrophages). The CD-68 positive cells were also distributed mainly around the arterioles. Fig. 9C is the screen capture image of the co-localization analysis on the software for LSM® (ZEN®, Carl Zeiss, Oberkochen, Germany). The brightness and saturation of pixels were equalized in spite of the intensities of the signals. The ratio of Cy-5 signals that co-localized with CD-68 signals to entire Cy-5 signals were 16.4 ± 1.4% (n = 7). 
Discussion
Our study demonstrated the relevance of nanomedicine size for targeting ALI, with 100-nm polymeric vesicles showing superior penetration, accumulation and retention, than the 200-nm version of the vesicles and 30-nm polymeric micelles. These findings were made possible by developing a novel disease model for ALI. Thus, several previous ALI models in rats, which are based on the longitudinal incision of the thigh and whole femoral artery resection or ligation [16] [17] [18] , require splitting the medial thigh muscles in the deep layer to ligate the popliteal and saphenous artery, which could induce surgical inflammation to the muscles of interest. On the other hand, we generated a new model by ligating the femoral artery just distal to the branching of the superficial epigastric artery, which offer two key advantages compared to previous whole femoral artery resection, as follows: First, it does not need longitude incision of thigh; Second, the procedure completes within just beneath the subcutaneous layer. Both of these factors contribute to reduce surgical inflammation on the thigh Fig. 6 . Quantitative analysis of the maximum radiant efficiency measured by IVIS® after 24 h of (A) PICs-30 group (n = 6), (B) PICs-100 group (n = 15), (C) PICs-200 group (n = 4), and 72 h of (D) PICs-30 group (n = 5), (E) PICs-100 group (n = 6), (F) PICs-200 group (n = 3). CF: caudofemoralis, SM: semimembranous, ST: semitendonous. *p < .05 (healthy vs ischemia). Fig. 7 . Ratio of the maximum radiant efficiency of ischemic side muscles to healthy side ones at (A) 24 h (n = 4-15) and (B) 72 h (n = 3-6) after PICs injections. CF: caudofemoralis, SM: semimembranous, ST: semitendonous. *p < .05 (vs PICs-30), **p < .05 (vs PICs-100).
muscles. Moreover, some procedures were simultaneously developed to evaluate the invasiveness. When we preserved the superficial epigastric artery, the collateral arteries tended to develop from internal iliac artery to femoral artery through the gracilis muscle -located superficially and adjacent to the femoral arteries. Although this method was less invasive, we believe it inappropriate for our model due to the surgical inflammatory effect on the focused muscles. In addition, we tried a more invasive procedure, which ligate the common iliac artery, though the thigh muscles fell into severe ischemia, which sometimes resulted in necrosis.
In this study, we have administrated various sizes of nanomedicines to elucidate the accumulation behavior in ALI. The size range of the nanomedicine models used in our work were based on previous studies targeting damaged vasculature, i.e. 40 nm PIC micelles in a balloon injury model of the rat carotid artery [14] and 106 nm PICsomes in an elastase infusion abdominal aortic aneurysm model [10] . In current study, we prepared 3 different size of nanomedicine analogues, i.e. 30 nm of PIC micelles, 100 and 200 nm of PICsomes, and found the fluorescent accumulation via the IVIS image in the PICs-100 and -200. However, PICs-30 did not show significant accumulation to the targeted muscles (Figs. 5-6 ). For PICs-30, previous report revealed the size-dependent plasma clearance of PICsome and PIC micelle [5] , and described the prolonged blood circulation of larger particle, e.g. PICsomes with ca.100-200 nm in diameter, compared with smaller formulations. These differences of blood circulation property may affect the accumulation to the targets. Moreover, it is assumed that collateral-forming muscles included CD-68 high positive cells in IHC of the ALI model, and the accumulation of PIC micelles and PICsomes is thought to be related this inflammatory reaction. Thus, the balance between the property of nano-particles and inflammation may also be important to obtain the selective accumulation into PAD. Regarding PICs-100 and -200, STRE comparison of the healthy side to the ischemic side showed the advantage of PICs-100 (Fig. 8) . Then we focused on the PICs-100 and inflammation in target muscles, and found that PICs-100 accumulated around the arterioles with moderate co-localization in CD-68 positive cells by immunofluorescent staining study. Additionally, we also found the character of the PICs-100 was retained even after 72 h from single intravenous injection by the inflammatory phagocyte, working as a signal of the local ischemic inflammation. A limitation of this study might be the difficulty to quantify the absolute amount of the accumulated PICs in the targeted vasculature, since the inflammatory parts in target muscles are small and restricted to inner vasculatures, which impairs the accurate weighing of these targets. Thus, the calculation of the absolute PICs amount in the inner vasculatures is currently impossible, though our results allowed us to estimate the targeting behavior of the PICs to the damage tissues.
The local injection of angiogenic agents in the muscle where the collateral vessels developed is a plausible treatment [15, 19] . However, clinically, limb ischemia patients have a variety of arterial diseased lesions and also the site of collateral vessels development varies. These heterogeneities limit the efficiency of local drug administration, in the present study, we found that the PICs-100 accumulated in the limited muscle, which was confirmed via microscopic study and IVIS assessment. We believe our results will have therapeutic implications in the future, including the establishment of ALI-targeted drug delivery systems for treatments, and the possibility to develop diagnosis systems based on clinically relevant imaging modalities, such as CT, MRI or fluorescent imaging [20, 21] .
Conclusions
In the present study, systemically injected PICs-100 and -200 accumulated to the caudofemoralis and semimembranous muscles, distributed around arterioles in those muscles, and remained several days after administration, whereas less accumulation and retention were observed in PICs-30. The accumulation efficiency was much higher for PICs-100 than for PICs-200. Given the importance of the size in nanomedicines for PAD targeting performed in this study, these size-controlled strategies will contribute to the future establishment of PAD directed imaging and therapeutic opportunities.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.jconrel.2018.07.049.
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